The Experts below are selected from a list of 384 Experts worldwide ranked by ideXlab platform
Miguel A. Gordo-vega - One of the best experts on this subject based on the ideXlab platform.
-
Peripapillary and macular choroidal thickness before and after phenylephrine instillation
Eye, 2019Co-Authors: Alfonso Casado, Alicia López-de-eguileta, Jorge Gaitán, Soraya Fonseca, Miguel A. Gordo-vegaAbstract:Objectives We investigated the effects of topical phenylephrine 2.5% instillation on choroidal thickness (CT), peripapillary choroidal thickness (pCT) and retinal nerve fibre layer (RNFL). Methods Healthy control patients underwent enhanced depth imaging (EDI) by spectral-domain optical coherence tomography (OCT) before and 30 min after phenylephrine instillation, using eye-tracking and follow-up software. Changes in 14 different locations of CT, 2 locations of pCT and RNFL were assessed. Results The study included 119 eyes of 62 patients (19 males and 43 females), with a mean age of 59.8 ± 15.3 years (range: 26-88 years). Within 30 min after instillation, the mean subfoveal CT both in vertical and horizontal scan were significantly thinned ( p = 0.005 and p = 0.018, respectively). In total, 1500, 1000 and 500 µm temporal CT measurements showed also a significant thinning ( p = 0.021, p = 0.037 and p = 0.020, respectively), as well as 500 µm both superior ( p = 0.045) and inferior ( p = 0.009). 1500, 1000 and 500 µm nasal CT, and 1500 and 1000 µm CT superior and inferior measurements showed no significant thinning after phenylephrine instillation. pCT was significantly thinned after phenylephrine in both superior ( p = 0.016) and inferior ( p = 0.050) measurements. RNFL analysis did not significantly change after phenylephrine instillation ( p = 0.209). Conclusions A significant thinning of CT and pCT occurred following phenylephrine instillation. Future studies analysing CT and pCT should detail if this Mydriatic Agent was used or not.
-
Peripapillary and macular choroidal thickness before and after phenylephrine instillation
Eye, 2019Co-Authors: Alfonso Casado, Alicia López-de-eguileta, Jorge Gaitán, Soraya Fonseca, Miguel A. Gordo-vegaAbstract:We investigated the effects of topical phenylephrine 2.5% instillation on choroidal thickness (CT), peripapillary choroidal thickness (pCT) and retinal nerve fibre layer (RNFL). Healthy control patients underwent enhanced depth imaging (EDI) by spectral-domain optical coherence tomography (OCT) before and 30 min after phenylephrine instillation, using eye-tracking and follow-up software. Changes in 14 different locations of CT, 2 locations of pCT and RNFL were assessed. The study included 119 eyes of 62 patients (19 males and 43 females), with a mean age of 59.8 ± 15.3 years (range: 26-88 years). Within 30 min after instillation, the mean subfoveal CT both in vertical and horizontal scan were significantly thinned (p = 0.005 and p = 0.018, respectively). In total, 1500, 1000 and 500 µm temporal CT measurements showed also a significant thinning (p = 0.021, p = 0.037 and p = 0.020, respectively), as well as 500 µm both superior (p = 0.045) and inferior (p = 0.009). 1500, 1000 and 500 µm nasal CT, and 1500 and 1000 µm CT superior and inferior measurements showed no significant thinning after phenylephrine instillation. pCT was significantly thinned after phenylephrine in both superior (p = 0.016) and inferior (p = 0.050) measurements. RNFL analysis did not significantly change after phenylephrine instillation (p = 0.209). A significant thinning of CT and pCT occurred following phenylephrine instillation. Future studies analysing CT and pCT should detail if this Mydriatic Agent was used or not.
Deborah T Modes - One of the best experts on this subject based on the ideXlab platform.
-
possible allergic reactions to cyclopentolate hydrochloride case reports with literature review of uses and adverse reactions
Ophthalmic and Physiological Optics, 1991Co-Authors: Lyndon Jones, Deborah T ModesAbstract:Cyclopentolate has been widely used as a cycloplegic and Mydriatic Agent for over 30 years. It has gained widespread use as the cycloplegic drug of first choice for most children over the age of I year and allows many optometrists and ophthalmologists lo carry out quick, successful cycloplegic refractions with few complications. During this time very few side-effects have been reported with the most commonly used 1 % solution. This paper outlines two cases in which a possible allergic-type reaction occurred shortly after the instillation of 1% cyclopentolate hydrochloride in ‘Minims’ form (Smith and Nephew). This article also reviews the uses and side-effects of cyclopentolate and aims to warn practitioners about the possibility of such reactions, ways of avoiding their occurrence and suitable measures to take should they occur.
Naoko Kato - One of the best experts on this subject based on the ideXlab platform.
-
iris posterior synechiae after descemet membrane endothelial keratoplasty in asian eyes prevention and management of posterior synechiae
Eye & Contact Lens-science and Clinical Practice, 2020Co-Authors: Yuji Kobashigawa, Toshiki Shimizu, Takahiko Hayashi, Hiroko Kobashigawa, Kentaro Yuda, Nobuhisa Mizuki, Norihiro Yamada, Naoko KatoAbstract:OBJECTIVES To evaluate the efficacy of a Mydriatic Agent for posterior synechiae after phacoemulsification and intraocular lens (IOL) implantation followed by Descemet membrane endothelial keratoplasty (staged DMEK). METHODS In this prospective study, the outcomes of DMEK with or without mydriasis (0.5% tropicamide and 0.5% phenylephrine hydrochloride [Mydrin-P; Santen, Osaka, Japan]) after the DMEK procedure were analyzed. Patients underwent IOL implantation approximately 4 weeks before DMEK. Six months after DMEK, the iris posterior synechiae severity score was evaluated based on the extent of posterior synechiae affecting the eight areas (45° each) of the pupillary rim (posterior synechiae score; grades 0-8). Best spectacle-corrected visual acuity, central corneal thickness, endothelial cell density, axial length, and the amount of air at the end of the surgery were also evaluated. RESULTS Fifteen eyes of 15 patients (Mydriatic: n=8, control: n=7) were eligible for inclusion. Iris posterior synechiae were detected in all seven eyes (100.0%) in the control group, whereas they were noted in two eyes in the Mydriatic group (25%). The mean iris posterior synechiae score was 0.69±1.20 in the Mydriatic group and was significantly lower than that in the control group (4.57±0.90; P<0.001). There was no significant difference in other clinical factors. Although the incidence and scores of posterior synechiae in the control group were higher, the incidence was significantly reduced with the use of a Mydriatic Agent (in the Mydriatic group). CONCLUSIONS Use of a Mydriatic Agent is an effective measure to prevent postoperative synechiae after DMEK.
-
Iris Posterior Synechiae After Descemet Membrane Endothelial Keratoplasty in Asian Eyes: Prevention and Management of Posterior Synechiae.
Eye & Contact Lens: Science & Clinical Practice, 2020Co-Authors: Yuji Kobashigawa, Toshiki Shimizu, Takahiko Hayashi, Hiroko Kobashigawa, Kentaro Yuda, Nobuhisa Mizuki, Norihiro Yamada, Naoko KatoAbstract:OBJECTIVES To evaluate the efficacy of a Mydriatic Agent for posterior synechiae after phacoemulsification and intraocular lens (IOL) implantation followed by Descemet membrane endothelial keratoplasty (staged DMEK). METHODS In this prospective study, the outcomes of DMEK with or without mydriasis (0.5% tropicamide and 0.5% phenylephrine hydrochloride [Mydrin-P; Santen, Osaka, Japan]) after the DMEK procedure were analyzed. Patients underwent IOL implantation approximately 4 weeks before DMEK. Six months after DMEK, the iris posterior synechiae severity score was evaluated based on the extent of posterior synechiae affecting the eight areas (45° each) of the pupillary rim (posterior synechiae score; grades 0-8). Best spectacle-corrected visual acuity, central corneal thickness, endothelial cell density, axial length, and the amount of air at the end of the surgery were also evaluated. RESULTS Fifteen eyes of 15 patients (Mydriatic: n=8, control: n=7) were eligible for inclusion. Iris posterior synechiae were detected in all seven eyes (100.0%) in the control group, whereas they were noted in two eyes in the Mydriatic group (25%). The mean iris posterior synechiae score was 0.69±1.20 in the Mydriatic group and was significantly lower than that in the control group (4.57±0.90; P
Alfonso Casado - One of the best experts on this subject based on the ideXlab platform.
-
Peripapillary and macular choroidal thickness before and after phenylephrine instillation
Eye, 2019Co-Authors: Alfonso Casado, Alicia López-de-eguileta, Jorge Gaitán, Soraya Fonseca, Miguel A. Gordo-vegaAbstract:Objectives We investigated the effects of topical phenylephrine 2.5% instillation on choroidal thickness (CT), peripapillary choroidal thickness (pCT) and retinal nerve fibre layer (RNFL). Methods Healthy control patients underwent enhanced depth imaging (EDI) by spectral-domain optical coherence tomography (OCT) before and 30 min after phenylephrine instillation, using eye-tracking and follow-up software. Changes in 14 different locations of CT, 2 locations of pCT and RNFL were assessed. Results The study included 119 eyes of 62 patients (19 males and 43 females), with a mean age of 59.8 ± 15.3 years (range: 26-88 years). Within 30 min after instillation, the mean subfoveal CT both in vertical and horizontal scan were significantly thinned ( p = 0.005 and p = 0.018, respectively). In total, 1500, 1000 and 500 µm temporal CT measurements showed also a significant thinning ( p = 0.021, p = 0.037 and p = 0.020, respectively), as well as 500 µm both superior ( p = 0.045) and inferior ( p = 0.009). 1500, 1000 and 500 µm nasal CT, and 1500 and 1000 µm CT superior and inferior measurements showed no significant thinning after phenylephrine instillation. pCT was significantly thinned after phenylephrine in both superior ( p = 0.016) and inferior ( p = 0.050) measurements. RNFL analysis did not significantly change after phenylephrine instillation ( p = 0.209). Conclusions A significant thinning of CT and pCT occurred following phenylephrine instillation. Future studies analysing CT and pCT should detail if this Mydriatic Agent was used or not.
-
Peripapillary and macular choroidal thickness before and after phenylephrine instillation
Eye, 2019Co-Authors: Alfonso Casado, Alicia López-de-eguileta, Jorge Gaitán, Soraya Fonseca, Miguel A. Gordo-vegaAbstract:We investigated the effects of topical phenylephrine 2.5% instillation on choroidal thickness (CT), peripapillary choroidal thickness (pCT) and retinal nerve fibre layer (RNFL). Healthy control patients underwent enhanced depth imaging (EDI) by spectral-domain optical coherence tomography (OCT) before and 30 min after phenylephrine instillation, using eye-tracking and follow-up software. Changes in 14 different locations of CT, 2 locations of pCT and RNFL were assessed. The study included 119 eyes of 62 patients (19 males and 43 females), with a mean age of 59.8 ± 15.3 years (range: 26-88 years). Within 30 min after instillation, the mean subfoveal CT both in vertical and horizontal scan were significantly thinned (p = 0.005 and p = 0.018, respectively). In total, 1500, 1000 and 500 µm temporal CT measurements showed also a significant thinning (p = 0.021, p = 0.037 and p = 0.020, respectively), as well as 500 µm both superior (p = 0.045) and inferior (p = 0.009). 1500, 1000 and 500 µm nasal CT, and 1500 and 1000 µm CT superior and inferior measurements showed no significant thinning after phenylephrine instillation. pCT was significantly thinned after phenylephrine in both superior (p = 0.016) and inferior (p = 0.050) measurements. RNFL analysis did not significantly change after phenylephrine instillation (p = 0.209). A significant thinning of CT and pCT occurred following phenylephrine instillation. Future studies analysing CT and pCT should detail if this Mydriatic Agent was used or not.
Mary K Daly - One of the best experts on this subject based on the ideXlab platform.
-
management of mydriasis and pain in cataract and intraocular lens surgery review of current medications and future directions
Clinical Ophthalmology, 2014Co-Authors: Seanna Grob, Luis Alonso Gonzalezgonzalez, Mary K DalyAbstract:The maintenance of mydriasis and the control of postoperative pain and inflammation are critical to the safety and success of cataract and intraocular lens replacement surgery. Appropriate mydriasis is usually achieved by topical and/or intracameral administration of anticholinergic Agents, sympathomimetic Agents, or both, with the most commonly used being cyclopentolate, tropicamide, and phenylephrine. Ocular inflammation is common after cataract surgery. Topical steroids and nonsteroidal anti-inflammatory drugs are widely used because they have been proved effective to control postsurgical inflammation and decrease pain. Topical nonsteroidal anti-inflammatory drugs have also been shown to help maintain dilation. However, use of multiple preoperative drops for pupil dilation, inflammation, and pain control have been shown to be time consuming, resulting in delays to the operating room, and they cause dissatisfaction among perioperative personnel; their use can also be associated with systemic side effects. Therefore, ophthalmologists have been in search of new options to streamline this process. This article will review the current medications commonly used for intraoperative mydriasis, as well as pain and inflammation control. In addition, a new combination of ketorolac, an anti-inflammatory Agent, and phenylephrine, a Mydriatic Agent has recently been designed to maintain intraoperative mydriasis and to reduce postoperative pain and irritation from intraocular lens replacement surgery. Two Phase III clinical trials evaluating this combination have demonstrated statistically significant differences when compared to placebo in maintaining intraoperative mydriasis (P<0.00001) and in reducing pain in the early postoperative period (P=0.0002). This medication may be of benefit for use in cataract and lens replacement surgery in the near future.
-
Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions
Clinical Ophthalmology, 2014Co-Authors: Seanna Grob, Luis Alonso Gonzalez-gonzalez, Mary K DalyAbstract:The maintenance of mydriasis and the control of postoperative pain and inflammation are critical to the safety and success of cataract and intraocular lens replacement surgery. Appropriate mydriasis is usually achieved by topical and/or intracameral administration of anticholinergic Agents, sympathomimetic Agents, or both, with the most commonly used being cyclopentolate, tropicamide, and phenylephrine. Ocular inflammation is common after cataract surgery. Topical steroids and nonsteroidal anti-inflammatory drugs are widely used because they have been proved effective to control postsurgical inflammation and decrease pain. Topical nonsteroidal anti-inflammatory drugs have also been shown to help maintain dilation. However, use of multiple preoperative drops for pupil dilation, inflammation, and pain control have been shown to be time consuming, resulting in delays to the operating room, and they cause dissatisfaction among perioperative personnel; their use can also be associated with systemic side effects. Therefore, ophthalmologists have been in search of new options to streamline this process. This article will review the current medications commonly used for intraoperative mydriasis, as well as pain and inflammation control. In addition, a new combination of ketorolac, an anti-inflammatory Agent, and phenylephrine, a Mydriatic Agent has recently been designed to maintain intraoperative mydriasis and to reduce postoperative pain and irritation from intraocular lens replacement surgery. Two Phase III clinical trials evaluating this combination have demonstrated statistically significant differences when compared to placebo in maintaining intraoperative mydriasis (P
